Clinical trials
Immune Thrombocytopenic Purpura clinical trials
Below are recruiting immune thrombocytopenic purpura clinical trials, each written for real people, not researchers. We’re tracking 14 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07194850RecruitingPhase 2/Phase 3
Study of Efgartigimod for teens with chronic ITP
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
BordeauxAges 12–17 - NCT06948318RecruitingPhase 3
Follow-up study of mezagitamab for chronic ITP
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hot Springs, ArkansasAges 18 years+ - NCT06722235RecruitingPhase 3
Mezagitamab for chronic ITP that hasn't responded to standard treatments
This study tests a new medicine called mezagitamab for adults with chronic ITP (low platelets for at least a year) who have not responded well to standard treatments. It aims to see if mezagitamab can safely raise platelet counts.
Hot Springs, ArkansasAges 18 years+ - NCT06831058RecruitingPhase 2
Efgartigimod for preventing iTTP relapses
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
Minneapolis, MinnesotaAges 18 years+ - NCT04323748RecruitingPhase 1
Testing a stronger rituximab dose schedule for new ITP
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
Vahalla, New YorkAges 1–21 - NCT07205861Recruiting
Study of patients with immune TTP in France
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
ParisAges Any age - NCT07513948Recruiting
Daratumumab treatment for immune-related blood clotting disorder
This trial studies how well a drug called daratumumab works for a rare blood disorder (iTTP) that causes dangerous clots and low platelet counts. Researchers want to understand if this treatment helps patients recover and stay healthy long-term.
MilanAges 18–99 - NCT07549698RecruitingPhase 1/Phase 2
CRISPR Gene Therapy for Immune Blood Disorders
This trial tests CTX112, a new CRISPR gene therapy that modifies your immune cells to treat severe immune thrombocytopenic purpura (ITP) or warm autoimmune hemolytic anemia (WAIHA) that hasn't responded to standard treatments. The goal is to see if it's safe and can help your body stop attacking its own blood cells.
Rochester, MinnesotaAges 18 years+ - NCT04890041Recruiting
Testing TPO medicines for immune low platelets in teens
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07441525RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat autoimmune blood diseases
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Wuhan, HubeiAges 18–75 - NCT07612319Recruiting
Romiplostim injection for treatment-resistant ITP
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
Suzhou, JiangsuAges 18 years+ - NCT06291025Recruiting
Testing a simpler treatment for immune-mediated TTP
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
AmiensAges 18 years+ - NCT06727669Recruiting
Long-term study of blood clotting and bleeding disorders
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
Beijing, Beijing MunicipalityAges Any age - NCT06928233Recruiting
TNF gene study in immune TTP patients
This study looks at a specific gene (TNFAIP3) in people who have had immune-mediated thrombotic thrombocytopenic purpura (iTTP). It aims to understand how this gene might be linked to the condition. Participants will provide a blood or DNA sample for genetic testing.
MilanAges 12 years+
Hear when a new Immune Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune thrombocytopenic purpura?
- Yes. Clin2 currently lists 14 recruiting immune thrombocytopenic purpura studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune thrombocytopenic purpura trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune thrombocytopenic purpura trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.